Texas has emerged as a dynamic hub for the biopharmaceutical industry, where companies are innovating therapies to address a variety of health challenges. This sector encompasses firms specializing in cancer treatments, immunotherapy, regenerative medicine, and pharmaceuticals for rare diseases. As technology evolves, there's a notable trend towards developing personalized medicines and leveraging advanced research methods, such as gene therapies. Moreover, Texas benefits from substantial funding and a strong workforce, contributing to a landscape ripe with prospects for breakthrough medical advancements. The integration of biotech firms into this space suggests a robust future for healthcare solutions originating from the Lone Star State.

The companies detailed in this list reflect a mix of sizes, ranging from startups with fewer than ten employees to firms with hundreds of employees, predominantly based in key cities like Houston, Austin, and Dallas. Founded mostly within the past few decades, they specialize in areas like cancer diagnostics, immunotherapies, and personalized medicine. Some companies, like Opexa Therapeutics and Radiomedix, are engaged in critical clinical trials, while others, like Cusabio Technology, focus on providing essential tools for research. Their varied backgrounds and fields of focus make them noteworthy contributors to Texas's biopharmaceutical ecosystem.

Continue reading to explore the top biopharmaceutical companies in Texas.

Top 19 Biopharmaceutical Companies Companies in Texas

1. Radiomedix, Inc.

• Website: radiomedix.com
• Ownership type: Private Equity
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $40.0M, October 2022
• Founded year: 2006
• Headcount: 11-50
• LinkedIn: radiomedix-inc-

Radiomedix, Inc., founded in 2006 and based in Houston, Texas, is a clinical-stage biotechnology company focused on developing targeted radiopharmaceuticals for the diagnosis and treatment of cancer. The company operates across the entire spectrum of drug development, from initial discovery through to commercial-scale manufacturing. Radiomedix is particularly noted for its work in positron emission tomography (PET) imaging and targeted therapies, utilizing both alpha and beta-emitting radiopharmaceuticals. Their facilities are compliant with regulatory standards, ensuring that they can conduct clinical trials and manufacture products that meet industry requirements. Recently, Radiomedix secured $40 million in Series A funding, which will likely bolster their research and development efforts and enhance their capabilities in the biopharmaceutical market.

2. Opexa Therapeutics

• Website: opexatherapeutics.com
• Ownership type: Corporate
• Headquarters: The Woodlands, Texas, United States (USA)
• Employee distribution: United States (USA) 68%, India 32%
• Latest funding: September 2017
• Founded year: 1986
• Headcount: 11-50
• LinkedIn: opexa-therapeutics

Opexa Therapeutics, based in The Woodlands, Texas, is a biotechnology firm established in 1986. The company specializes in the development of personalized immunotherapies aimed at treating autoimmune diseases, with a particular focus on multiple sclerosis (MS) and neuromyelitis optica (NMO). Their flagship product, Tcelna®, is a personalized T-cell immunotherapy currently in Phase IIb clinical trials, specifically designed to address Secondary Progressive MS. Opexa's proprietary T-cell technology, ImmPath®, allows for tailored treatments that align with individual patient immune responses. The company also works on OPX-212, another autologous T-cell therapy targeting NMO. Opexa's operations include a cGMP manufacturing facility and ongoing clinical research, underscoring their commitment to advancing precision medicine in the biopharmaceutical sector.

3. Orano Med

• Website: oranomed.com
• Ownership type: Private
• Headquarters: Plano, Texas, United States (USA)
• Employee distribution: France 55%, United States (USA) 42%, Other 2%
• Founded year: 2009
• Headcount: 51-200
• LinkedIn: areva-med-llc

Orano Med, founded in 2009 and based in Plano, Texas, is a biotechnology firm dedicated to advancing cancer treatment through innovative therapies. The company specializes in Targeted Alpha Therapy (TAT), utilizing lead-212, a potent alpha-emitting radioisotope, to create targeted treatments for various cancers. Orano Med's mission is to address significant unmet medical needs in oncology, focusing on patients who do not respond to existing therapies. They have established a robust pipeline of 212Pb-based therapies and are committed to ensuring a reliable supply chain for these drugs. With two ongoing clinical trials and a strong emphasis on research and development, Orano Med is positioned to make a meaningful impact in the biopharmaceutical industry. Their facilities in both the United States and France support preclinical and clinical development, showcasing their commitment to advancing cancer therapies.

4. Tvardi Therapeutics

• Website: tvardi.com
• Ownership type: Private
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2017
• Headcount: 1-10
• LinkedIn: tvardi

Tvardi Therapeutics is a clinical-stage biopharmaceutical company based in Houston, Texas, founded in 2017. The company is dedicated to developing novel oral small molecule therapies targeting STAT3, a protein implicated in cancer and fibrotic diseases. Their primary product, TTI-101, is currently in multiple clinical trials aimed at treating conditions such as liver cancer and idiopathic pulmonary fibrosis (IPF). Tvardi's approach is rooted in addressing significant unmet medical needs, and their research has shown promising results in early trials. The company is led by a team of experienced professionals from prestigious institutions, including the University of Texas MD Anderson Cancer Center, which adds credibility to their scientific endeavors. Tvardi's commitment to innovation and patient care positions it as a noteworthy player in the biopharmaceutical industry.

5. Iterion Therapeutics

• Website: iteriontherapeutics.com
• Ownership type: Venture Capital
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $17.0M, February 2021
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: iterion-therapeutics

Iterion Therapeutics, based in Houston, Texas, is a clinical-stage biopharmaceutical company founded in 2014. The company is dedicated to developing novel therapeutics for cancer, with a particular focus on their lead product, tegavivint. This first-in-class small molecule inhibitor targets the Wnt/beta-catenin signaling pathway, which is implicated in numerous cancers. Iterion is actively engaged in clinical trials, including a recent Phase 1b/2a trial for patients with advanced hepatocellular carcinoma. Their approach aims to address significant unmet needs in oncology, and they collaborate with healthcare providers and research institutions to enhance treatment options. The company has received $17 million in Series B funding as of February 2021, which supports their ongoing research initiatives and clinical development efforts.

6. Peloton Therapeutics

• Website: pelotontherapeutics.com
• Ownership type: Corporate
• Headquarters: Dallas, Texas, United States (USA)
• Latest funding: May 2019
• Founded year: 2011
• Headcount: 11-50
• LinkedIn: peloton-therapeutics

Peloton Therapeutics, Inc. is a clinical stage pharmaceutical company based in Dallas, Texas, founded in 2011. The company is dedicated to translating novel scientific insights into first-in-class medicines aimed at treating cancer and other life-threatening conditions. Peloton is particularly focused on HIF-2α, a transcription factor that has been challenging to target with small molecules. They have pioneered the first HIF-2α therapy to enter clinical development, showcasing their innovative approach to drug discovery. Peloton's research efforts are centered on identifying new compounds that can effectively modulate complex protein-protein interactions involved in disease processes. Their pipeline includes programs targeting kidney cancer and VHL Disease, indicating a clear commitment to addressing significant medical needs. Peloton Therapeutics serves patients and healthcare providers seeking advanced treatment options, positioning themselves as a notable entity in the biopharmaceutical industry.

7. ImmunoGenesis, Inc.

• Website: immunogenesis.com
• Ownership type: Venture Capital
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: December 2020
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: immunogenesis-inc

ImmunoGenesis, Inc. is a biopharmaceutical company based in Houston, Texas, founded in 2019. The company specializes in immuno-oncology, focusing on developing therapies for cold tumors, which are characterized by a lack of activated T cells and other immune resistance mechanisms. Their lead products include IMGS-001, a dual-specific PD-L1/PD-L2 inhibitor designed to enhance immune response in these challenging cases, and IMGS-101, a hypoxia-reversal agent aimed at improving T cell access to tumors. ImmunoGenesis is currently advancing its clinical programs, with IMGS-001 having entered Phase 1a/1b trials in late 2023. The company operates from JLABS @ TMC, a biotech incubator that supports their innovative research and development efforts. Their strategic focus on cold tumors addresses a significant gap in cancer treatment, as these tumors represent a large portion of cancer cases with limited effective therapies.

8. Triumvira Immunologics, Inc.

• Website: triumvira.com
• Ownership type: Venture Capital
• Headquarters: Austin, Texas, United States (USA)
• Employee distribution: United States (USA) 65%, Canada 35%
• Latest funding: Series A, $45.0M, March 2022
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: triumvira-immunologics-inc

Triumvira Immunologics, Inc. is a biotechnology firm based in Austin, Texas, founded in 2015. The company specializes in developing innovative T cell therapies aimed at treating cancer. Their primary focus is on the T cell Antigen Coupler (TAC) technology, which enhances the immune system's ability to recognize and destroy tumor cells. Triumvira operates through clinical trials and partnerships to advance its therapeutic programs, particularly targeting difficult-to-treat tumors. The company has a robust pipeline, including their lead candidate, TAC101-CLDN18.2, which is designed for claudin 18.2-positive solid tumors. Triumvira has secured significant funding, with a recent Series A round raising $45 million in March 2022, which supports their research and development efforts. With a dedicated team and a strong intellectual property portfolio, Triumvira is positioned to make a meaningful impact in the field of immuno-oncology.

9. Renibus Therapeutics Inc

• Website: renibus.com
• Ownership type: Venture Capital
• Headquarters: Southlake, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $25.0M, September 2023
• Founded year: 2016
• Headcount: 201-500
• LinkedIn: renibus-therapeutics-inc

Renibus Therapeutics Inc, based in Southlake, Texas, is a biopharmaceutical company established in 2016. The company is dedicated to developing innovative therapies aimed at improving outcomes for patients suffering from cardio, renal, and metabolic diseases. Their flagship product, RBT-1, is a first-in-class intravenous drug designed to reduce postoperative complications in patients undergoing elective cardiac and valve surgeries. Currently in a Phase 3 pivotal trial, RBT-1 has garnered FDA Breakthrough and Fast Track Designations, underscoring its potential significance in the medical field. Additionally, Renibus has acquired Veverimer, an oral hydrochloric acid binder, which targets gastrointestinal issues and orphan diseases. The company is actively involved in clinical trials and engages with healthcare providers to enhance treatment outcomes. With a recent Series B funding round raising $25 million in September 2023, Renibus is positioned to further its research and development efforts in the biopharmaceutical industry.

10. Cusabio Technology LLC

• Website: cusabio.com
• Ownership type: Private
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: China 100%
• Founded year: 2007
• Headcount: 501-1000
• LinkedIn: cusabio

Cusabio Technology LLC, founded in 2007 and based in Houston, Texas, is a private biotechnology firm that specializes in life sciences research. The company offers a wide array of products, including antibodies, proteins, and ELISA kits, which are essential tools for researchers in the pharmaceutical and biotechnology sectors. Cusabio is particularly noted for its contributions to drug development and vaccine research, providing high-quality reagents and technical services that support various stages of research. Their product offerings extend to mRNA vaccine research solutions and CAR-T therapy development, showcasing their commitment to advancing innovative therapies. With a workforce of around 500 to 1000 employees, Cusabio has established itself as a reliable partner for organizations seeking to enhance their research capabilities.

11. Cellenkos, Inc.

• Website: cellenkosinc.com
• Ownership type: Corporate
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: April 2022
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: cellenkos-inc.

Cellenkos, Inc., founded in 2016 and based in Houston, Texas, is a biotechnology company dedicated to the development of allogeneic T regulatory cell therapies. The firm specializes in addressing autoimmune diseases and inflammatory disorders through innovative therapeutic solutions derived from umbilical cord blood. Their flagship product, CK0801, is designed to replace defective T regulatory cells, aiming to restore immune balance and control disease progression. Cellenkos operates through clinical trials and research partnerships, including collaborations with MD Anderson Cancer Center, to advance their therapeutic offerings. The company has also engaged in strategic partnerships, such as with Incyte Pharmaceuticals, to explore combination therapies, enhancing their research and development capabilities. Cellenkos is committed to providing advanced treatment options for patients and healthcare providers, focusing on high unmet medical needs in the biopharmaceutical sector.

12. Signature Biologics

• Website: signaturebiologics.com
• Ownership type: Private
• Headquarters: Irving, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2007
• Headcount: 11-50
• LinkedIn: signaturebiologics

Signature Biologics, founded in 2007 and based in Irving, Texas, is a biotechnology company that specializes in the development and manufacturing of cellular therapeutics and biologics. The company is dedicated to using innovative techniques to produce high-quality human cellular products, primarily serving healthcare providers and organizations in the regenerative medicine sector. Their mission emphasizes rigorous scientific and clinical study, ensuring that their products enhance patient care. Signature Biologics operates under strict quality management systems, holding ISO 9001:2015 certification and accreditation from the American Association of Tissue Banks (AATB). The leadership team, including founder Dr. Neil Riordan, brings decades of experience in applied stem cell research and regenerative medicine. The company is positioned to grow as it continues to develop advanced therapeutic solutions that address various medical needs.

13. OncoNano Medicine, Inc.

• Website: onconano.com
• Ownership type: Venture Capital
• Headquarters: Southlake, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $18.4M, October 2021
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: onconano-medicine

OncoNano Medicine, Inc. is a biotechnology company based in Southlake, Texas, founded in 2014. The company specializes in developing innovative cancer therapies through its proprietary ON-BOARD™ nanotechnology platform. This platform is designed to enhance drug delivery specifically to tumor sites, improving treatment efficacy while minimizing systemic exposure. OncoNano is currently advancing a pipeline of therapies, including ONM-501, a dual-activating STING agonist, and Pegsitacianine, a pH-sensitive fluorescent nanoprobe for real-time surgical imaging. The company is actively involved in clinical trials to validate its therapies, demonstrating a commitment to improving patient outcomes in oncology. In October 2021, OncoNano secured $18.4 million in Series B funding, reflecting strong investor confidence in its innovative approach to cancer treatment.

14. Evestra, Inc.

• Website: evestra.com
• Ownership type: Private
• Headquarters: Schertz, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Convertible note, $1.8M, December 2009
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: evestra-inc.

Evestra, Inc. is a private biopharmaceutical company based in Schertz, Texas, founded in 2020. The company specializes in developing innovative products aimed at improving women's health. Evestra's focus areas include fertility control, endometriosis, hormone replacement therapy, and oncology. They utilize advanced medicinal chemistry and drug delivery technologies to create their products. Evestra has a clinical-stage product pipeline, which includes both pre-clinical and clinical-stage products, and all their offerings are protected by broad US and international patents. The company has also received significant funding, including a grant from the Bill and Melinda Gates Foundation to develop a long-acting injectable contraceptive aimed at underserved populations. This funding highlights their commitment to addressing global health challenges and improving access to women's healthcare solutions.

15. Santa Cruz Biotechnology (SCBT)

• Website: scbt.com
• Ownership type: Private
• Headquarters: Dallas, Texas, United States (USA)
• Employee distribution: United States (USA) 87%, China 10%, Germany 4%
• Founded year: 1991
• Headcount: 201-500
• LinkedIn: santa-cruz-biotechnology

Santa Cruz Biotechnology, Inc. (SCBT), founded in 1991 and based in Dallas, Texas, is a private biotechnology company that specializes in the production and distribution of laboratory products. The company offers a wide array of products, including primary monoclonal antibodies, gene editing tools such as CRISPR, and various laboratory chemicals. SCBT serves a clientele that includes researchers and laboratories in the biotechnology and pharmaceutical sectors, providing them with essential tools for scientific research and experimentation. Their extensive catalog supports a range of applications, from basic research to advanced therapeutic development. SCBT's commitment to quality and innovation in laboratory supplies has made it a trusted source for many in the scientific community.

16. Vgxi

• Website: vgxii.com
• Ownership type: Private
• Headquarters: Conroe, Texas, United States (USA)
• Employee distribution: United States (USA) 98%, Other 2%
• Founded year: 1997
• Headcount: 51-200
• LinkedIn: vgxi-inc

Vgxi, founded in 1997 and based in Conroe, Texas, is a private biopharmaceutical manufacturer that specializes in the production of plasmid DNA. Their services cater to the needs of biotech and pharmaceutical companies, focusing on applications in gene therapy, cell therapy, and immunotherapy. Vgxi offers a range of services including pre-clinical and cGMP plasmid manufacturing, process development, and stability testing. With a workforce of approximately 117 employees, the company has established itself as a reliable partner for clients requiring high-quality plasmids for clinical trials and therapeutic development. Their state-of-the-art facilities and commitment to quality management ensure that they meet rigorous international regulatory standards, making them a valuable asset in the biopharmaceutical supply chain.

17. Maxwell Biosciences

• Website: maxwellbiosciences.com
• Ownership type: Venture Capital
• Headquarters: Austin, Texas, United States (USA)
• Employee distribution: United States (USA) 75%, India 12%, Canada 12%
• Latest funding: January 2023
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: maxwell-biosciences

Maxwell Biosciences, founded in 2016 and based in Austin, Texas, is a biotechnology firm dedicated to developing synthetic immune system technologies. The company is particularly focused on creating therapeutics to combat infectious diseases, leveraging its proprietary Claromer® platform. This platform aims to produce effective treatments for a range of pathogens, including those resistant to current antibiotics. Maxwell's research is rooted in a scientific understanding of immunosenescence, the decline of immune function with age, and seeks to reverse this process through innovative drug candidates. The company has received positive feedback from the FDA regarding its upcoming human trials, which are set to begin in 2025. Maxwell's team includes experienced professionals from the pharmaceutical industry, enhancing its capability to navigate the complexities of drug development. Their work is supported by collaborations with prestigious research institutions, underscoring their commitment to advancing healthcare solutions.

18. PanTher Therapeutics

• Website: panthertx.com
• Ownership type: Venture Capital
• Headquarters: Austin, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: June 2023
• Founded year: 2016
• Headcount: 1-10
• LinkedIn: panther-therapeutics

PanTher Therapeutics, founded in 2016 and based in Austin, Texas, is a biotechnology firm dedicated to transforming cancer treatment through innovative drug delivery systems. The company specializes in localized, high-dose chemotherapy treatments that target tumors directly, aiming to enhance therapeutic efficacy while reducing systemic toxicity. Their proprietary Sagittari platform allows for the continuous release of chemotherapeutic agents at the tumor site, significantly increasing drug concentration where it is most needed. Currently, PanTher is advancing its lead product candidate, PTM-101, which is in clinical development for pancreatic cancer. The company has also received funding to support its research initiatives, demonstrating its commitment to addressing the challenges in oncology. With a small team of skilled professionals, PanTher is focused on redefining cancer therapy and improving patient outcomes through its innovative approaches.

19. IntraBio Inc

• Website: intrabio.com
• Ownership type: Private
• Headquarters: Austin, Texas, United States (USA)
• Employee distribution: United States (USA) 68%, United Kingdom (UK) 32%
• Latest funding: $40.3M, March 2024
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: intrabio-inc

IntraBio Inc, founded in 2015 and based in Austin, Texas, is a private biopharmaceutical company dedicated to developing innovative therapies for rare neurodegenerative diseases. The company is actively engaged in clinical trials to assess the efficacy and safety of its lead product, IB1001, which targets conditions such as Niemann-Pick Disease Type C and GM2 Gangliosidosis. IntraBio's research is rooted in the expertise of its scientific founders from prestigious institutions like the University of Oxford and the University of Munich. The company has made strides in its clinical programs, with IB1001 demonstrating significant improvements in symptoms and quality of life for patients in pivotal trials. In March 2024, IntraBio announced that the FDA accepted its New Drug Application for IB1001, further solidifying its position in the biopharmaceutical sector. The company has also secured substantial funding, amounting to over $40 million, which reflects strong investor interest in its mission to address high unmet medical needs in the field of neurodegenerative diseases.

Biopharmaceutical Companies Insights: Key Companies in Texas

Want to Find More Biopharmaceutical Companies Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!